-+ 0.00%
-+ 0.00%
-+ 0.00%

AstraZeneca: In the TITANIA study, Tozorakimab 300mg reduced the risk of moderate to severe acute exacerbations by 29% in the overall COPD patient population who currently and previously smoked.

Zhitongcaijing·09/08/2026 11:49:01
Listen to the news
AstraZeneca: In the TITANIA study, Tozorakimab 300mg reduced the risk of moderate to severe acute exacerbations by 29% in the overall COPD patient population who currently and previously smoked.